6 April 2018 - - Philadelphia, Pennsylvania-based biotherapeutics company Tmunity Therapeutics, Inc. has appointed Jason Krentz as chief technology officer and head of technical operations,.
In his management role at Tmunity, Krentz will be responsible for all aspects of the company's manufacturing and technical operations including development and leadership of key functions, including manufacturing sciences, process and analytical development, cGMP manufacturing operations, quality control and assurance and facilities management.
He will also work closely with the staff at the University of Pennsylvania and external partners to identify, evaluate, develop and implement manufacturing process improvements, process automation and analytical technologies to improve manufacturing robustness and reliability.
Krentz formerly served in manufacturing and technical operations leadership roles at Endo Pharmaceuticals, Auxilium Pharmaceuticals, and Tengion.
Krentz holds a Master of Business Administration degree from St. Joseph's University and a Bachelor of Science degree in Materials Science and Engineering from the University of Michigan.
Privately held Tmunity Therapeutics is developing novel treatments that exhibit control over T cell activation and direction in the body.
These personalised next-generation immunotherapies for cancer, infectious disease, and autoimmune disease are advancing rapidly toward the clinic. The company utilizes laboratories and production facilities at UPenn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of T cell therapies.